United Healthcare Services, Inc. v. AmerisourceBergen Corporation
- Donovan Frank
- 0:23-cv-02890
- U.S. District Court · District of Minnesota
- 24
In United Healthcare Services, Inc. v. AmerisourceBergen Corporation, Judge Frank dismissed with prejudice all claims brought by health insurer United Healthcare Services against pharmaceutical distributor AmerisourceBergen and related companies, finding that the insurer failed to plausibly allege fraud, unjust enrichment, or related claims and that its claims were also filed too late.
Commercial health insurers who reimburse claims for drugs distributed through third-party providers may be affected, as the ruling makes clear that indirect payers—those with no direct relationship to a defendant—face significant obstacles in bringing fraud and unjust enrichment claims under Minnesota law. Healthcare companies and pharmaceutical distributors involved in drug distribution chains are also affected.
What happened
In United Healthcare Services, Inc. v. AmerisourceBergen Corporation, health insurer United Healthcare Services (UHS) sued AmerisourceBergen and several related companies, alleging that between 2001 and 2014 the defendants ran an unlawful scheme to distribute pre-filled syringes of oncology drugs that were adulterated or otherwise non-compliant with federal drug law. UHS claimed it was harmed because it reimbursed insurance claims submitted by healthcare providers who had purchased and administered those drugs to patients insured under UHS plans. The underlying misconduct had already resulted in a 2017 criminal guilty plea and a 2018 civil settlement with the federal government totaling hundreds of millions of dollars, but UHS—a commercial insurer—filed its own lawsuit in September 2023.
UHS brought six claims: common law fraud, three Minnesota consumer-protection statutes, a state law protecting senior citizens from deceptive acts, and unjust enrichment. The court examined each theory carefully. On the fraud claims, the court found that the statements UHS pointed to as false—such as pledges to 'follow the letter of the law' and promote 'patient safety'—were too vague and general to count as actionable fraud (a concept called 'puffery'). Statements made after the program ended in 2014 could not have caused UHS to reimburse claims during the program. Statements made to third parties like doctors and regulators, rather than to UHS directly, did not establish the required reliance or causal link to UHS's losses. The court also rejected UHS's argument that defendants had a duty to disclose information to UHS, because the two sides had no direct relationship—providers bought from defendants, administered drugs to patients, and only then submitted reimbursement claims to UHS.
Judge Frank granted the defendants' motion to dismiss and dismissed all claims with prejudice, meaning UHS cannot refile them. The court also found the claims independently time-barred, noting that public disclosures about the scheme began as early as 2012 and that UHS's own fraud theory—that it relied on defendants' statements over the years—was inconsistent with its separate argument that it could not have discovered the fraud until after November 2016. The court acknowledged that defendants engaged in significant misconduct that had already led to serious legal consequences through government enforcement, but concluded that UHS as a commercial insurer had not adequately stated any legal claim for the same conduct.
The detailed version
- United Healthcare Services, Inc. v. AmerisourceBergen Corporation, Civil No. 23-2890 (DWF/ECW)
- Donovan W. Frank, United States District Judge
- October 2, 2025
Background and Parties Plaintiff United Healthcare Services, Inc. (UHS) is a commercial health insurer. Defendants are AmerisourceBergen Corporation, its subsidiaries AmerisourceBergen Drug Corporation and AmerisourceBergen Specialty Group, LLC (ABC Specialty), ASD Specialty Healthcare LLC d/b/a Oncology Supply, and Medical Initiatives, Inc. d/b/a Oncology Supply Pharmacy Services (MII). MII was acquired by AmerisourceBergen in 2001 and operated a facility in Dothan, Alabama.
Underlying Conduct From 2001 to January 2014, MII created pre-filled syringes (PFSs) of oncology drugs by drawing medication from manufacturer vials, retaining 'overfill' from those vials to fill additional prescriptions, and shipping the syringes to healthcare providers. ABC Specialty sold or distributed these PFSs. UHS alleged that MII's process was non-sterile, lacked required quality assurance, violated federal manufacturing standards, and produced 'adulterated, dangerous, tainted, effectively worthless' drugs. Defendants did not sell directly to UHS; providers purchased PFSs, administered them to patients, and submitted reimbursement claims to insurers including UHS subsidiaries.
The conduct was publicly disclosed in Securities and Exchange Commission (SEC) filings beginning around 2010 and in news reports. In September 2017, ABC Specialty pleaded guilty to a strict-liability misdemeanor under the Federal Food, Drug, and Cosmetic Act (FDCA) and agreed to pay $208 million in criminal fines and $52 million in criminal forfeiture. In October 2018, defendants entered a civil settlement under the False Claims Act for $625 million covering federal and state Medicaid programs.
UHS filed this lawsuit on September 19, 2023. The court had previously dismissed the original complaint as time-barred in April 2024, then partially granted relief, vacated judgment, and allowed UHS to file a First Amended Complaint (FAC) to attempt to cure pleading deficiencies. Defendants then moved to dismiss the FAC.
Claims Alleged UHS's FAC alleged: (1) common law fraud/fraudulent concealment; (2) violation of the Minnesota Consumer Fraud Act (Minn. Stat. § 325F.69); (3) Minnesota Unlawful Trade Practices Act (Minn. Stat. § 325D.13); (4) deceptive acts against senior citizens (Minn. Stat. § 325F.71); (5) Minnesota Unfair and Deceptive Trade Practices Act (Minn. Stat. § 325D.44); and (6) unjust enrichment/money had and received.
Legal Standards Applied The court applied the Rule 12(b)(6) pleading standard (requiring enough facts to state a plausible claim for relief under Twombly/Iqbal) and the heightened Rule 9(b) particularity requirement for fraud claims, which demands the 'who, what, when, where, and how' of the alleged fraud.
Fraud Claims — Statements Received by UHS UHS pointed to specific statements on defendants' websites and publications from 2011, 2016, and 2022, including pledges to 'follow the letter of the law,' 'err on the safe side,' prioritize 'patient safety,' and deliver 'cutting-edge compliance solutions.' The court found these statements constituted non-actionable 'puffery'—too vague and general to be actionable under common law or consumer fraud statutes—citing Bernstein v. Extendicare Health Services, Inc. The court also found that most of these statements postdated the end of the PFS Program in 2014, so they could not have caused UHS to reimburse claims during the program. UHS's allegation that defendants' website was 'materially consistent' over time and that other statements from the relevant period existed was insufficient under Rule 9(b) because it lacked supporting facts.
Fraud Claims — Statements to Third Parties UHS also alleged defendants made false representations to healthcare providers and regulators, including: (1) that PFSs contained FDA-approved drugs; and (2) that MII was a licensed pharmacy. The court found that representing the PFSs as containing FDA-approved medication was a reasonable interpretation of the FDCA's definition of 'new drug,' which focuses on the composition of the drug, and therefore not fraudulent. The court also found UHS failed to establish that defendants' admission in the DOJ settlement meant MII was not a pharmacy; the plea agreement showed MII was a licensed pharmacy in multiple states, even if it did not qualify for a registration exemption as a repackager.
More fundamentally, the court found that UHS failed to plead reliance or causation with the specificity required by Rule 9(b). UHS did not allege what false information appeared in insurance claim forms, whether any false information actually reached UHS, or who at UHS relied on any such information. The court also declined to apply an 'indirect reliance' theory (where misstatements to a third party are passed through to the plaintiff) because UHS failed to allege the 'effect' of defendants' statements reached UHS, distinguishing the case from Corp. Commission of Mille Lacs Band of Ojibwe Indians v. Money Centers of America, Inc.
Fraud Claims — Omissions UHS alleged defendants fraudulently omitted material information. Under Minnesota law, nondisclosure is fraudulent only if the defendant had a legal or equitable duty to disclose to the plaintiff. Because defendants had no direct relationship with UHS—they sold to providers, not to UHS—the court found no such duty existed. The court also declined to extend the duty to disclose based on 'half-truths,' finding the cases UHS cited involved direct transactions between parties rather than the indirect chain at issue here.
Unjust Enrichment UHS claimed it 'conferred direct benefits' on defendants when reimbursing claims for PFSs. The court dismissed this claim because UHS paid providers and pharmacies—not defendants—and defendants did not receive UHS's money. An essential element of unjust enrichment under Minnesota law is that the defendant actually received a benefit at the plaintiff's expense, which was not adequately alleged. The money-had-and-received theory failed for the same reason.
Timeliness The court found UHS's claims independently time-barred. Public disclosures of the alleged scheme began in 2012, yet UHS filed suit in 2023. The court also noted an internal inconsistency in UHS's theory: UHS argued it could not have discovered the fraud before November 2016 (to avoid a limitations bar), yet simultaneously argued it relied on defendants' statements made years before 2016. These positions are mutually inconsistent. UHS's fraudulent concealment tolling argument also failed because the allegedly concealing conduct was directed at physicians, regulators, and the public—not UHS—and UHS could not show it could not have discovered the fraud with reasonable diligence given public disclosures starting in 2012.
Disposition The court granted defendants' motion to dismiss in its entirety. All claims in the First Amended Complaint were dismissed with prejudice (meaning UHS cannot refile these claims). The court noted that defendants' misconduct had already resulted in significant government enforcement consequences, but that UHS as a commercial insurer had not adequately stated any cognizable legal claim.
Reviewer note from the AI+
Read the full 24-page opinion on CourtListener, the free public archive maintained by the Free Law Project.